VEEV Raises FY27 Outlook as Vault CRM and AI Momentum Accelerate Fast

Veeva Systems Inc. VEEV raised its fiscal 2027 outlook after second-quarter revenues increased 17.6% year over year to $928 million. Vault CRM adoption and broader commercial execution added another positive signal.

The question is how quickly CRM migrations, newer R&D products and Falcon can extend growth without raising execution risk. Veeva’s guidance points to continued profitability, but several newer initiatives are still early.

VEEV Raises Its Fiscal 2027 Financial Targets

Veeva now expects fiscal 2027 revenues of $3.682-$3.687 billion, subscription revenues of about $3.08 billion and adjusted earnings of roughly $9.21 per share. The revenue outlook implies about 15% growth at the high end.

Management also projects approximately $1.64 billion in non-GAAP operating income, with a roughly 44% non-GAAP operating margin. That combination keeps profitability intact while the company continues investing in product development and artificial intelligence.

Image Source: Zacks Investment Research

Veeva’s Vault CRM Migration Reaches New Milestones

Vault CRM recorded its best quarter to date, with two additional top-20 biopharma selections. Veeva now has commitments from 12 of the top 20, while more than 180 customers are already live on Vault CRM.

The migration can also deepen adoption across Veeva’s Commercial Cloud. Salesforce, Inc. CRM, which competes in CRM and agentic software, reported second-quarter fiscal 2027 revenues of $11.3 billion, up 11% year over year, underscoring the scale of enterprise CRM and AI competition.

VEEV’s Falcon AI Adds a New Growth Avenue

Falcon moves Veeva into agentic labor for workflows such as clinical document processing and safety case intake. Five customers are early adopters, including a top-20 pharma company, and first go-lives are expected in 2026.

Customer interest is running ahead of product readiness. Management said Veeva is currently the rate limiter as it works to prove agent quality, operating processes and human-review controls, making execution more important than near-term Falcon revenues.

Veeva’s R&D Portfolio Broadens the Growth Base

Veeva’s R&D and Quality subscription revenues rose 19% year over year to $419.4 million in the second quarter. Management expects newer products, including EDC, eCOA, RTSM, Safety and LIMS, to become more important as mature applications grow more slowly.

IQVIA Holdings Inc. IQV provides another life-sciences technology comparison. Its second-quarter 2026 revenues rose 8.7% to $4.37 billion, with both Commercial Solutions and R&D Solutions expanding, highlighting continued spending across life-sciences data, technology and research workflows.

Image Source: Zacks Investment Research

VEEV Must Convert Innovation Into Durable Growth

The guidance increase and product progress raise the execution bar. Continued CRM migrations must translate into successful deployments and broader Commercial Cloud adoption, while the newer R&D applications need to offset slower growth in established products.

Falcon adds another layer of opportunity, but monetization remains early. Pricing is still being developed and management is not relying on material near-term Falcon revenues, so product readiness and customer outcomes will be key indicators of progress.

VEEV’s Style Scores Reflect the Mixed Setup

The investment setup remains balanced. Veeva is delivering mid-teens growth, high adjusted operating profitability and broader product momentum, but Vault CRM migrations and newer AI and R&D products still require sustained execution.

VEEV currently carries a Zacks Rank #3 (Hold), with a Value Score of D, a Growth Score of B, a Momentum Score of A and a VGM Score of B. The favorable Growth and Momentum Scores support the company’s operating and share-price trends, while the weaker Value Score tempers the setup. The Hold rank and B VGM Score point to a measured near-term view rather than a clear-cut directional signal.

You can see the complete list of today’s Zacks #1 Rank (Strong Buy) stocks here. 

Research Chief Names "Single Best Pick to Double"

From thousands of stocks, 5 Zacks experts each have chosen their favorite to skyrocket +100% or more in months to come. From those 5, Director of Research Sheraz Mian hand-picks one to have the most explosive upside of all.

This company targets millennial and Gen Z audiences, generating nearly $1 billion in revenue last quarter alone. A recent pullback makes now an ideal time to jump aboard. Of course, all our elite picks aren’t winners but this one could far surpass earlier Zacks’ Stocks Set to Double like Nano-X Imaging which shot up +129.6% in little more than 9 months.

Want the latest recommendations from Zacks Investment Research? Today, you can download 7 Best Stocks for the Next 30 Days. Click to get this free report

This article originally published on Zacks Investment Research (zacks.com).

Zacks Investment Research